Industry Consolidation To Bring Long-Term Benefits

Continuing the consolidation trend in the European pharmaceutical sector, Belgian firm UCB has unveiled a EUR4.4bn (US$5.6bn) bid for German company Schwarz Pharma to create major biopharmaceutical player specialising in neurology, inflammation and oncology.

To read the full article, please choose one of the following options: